Successful Treatment of Chronic Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases by Totté, J.E.E. (Joan) et al.
  
Case Rep Dermatol 2017;9:19–25 
DOI: 10.1159/000473872 
Published online: May 22, 2017 
© 2017 The Author(s) 
Published by S. Karger AG, Basel 
www.karger.com/cde 
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes requires written permission. 
 
 
           
 
 Joan E.E. Totté 
Department of Dermatology, Erasmus MC University Medical Center Rotterdam 
Burgemeester s’ Jacobplein 51 
NL–3015 CA Rotterdam (The Netherlands) 
E-Mail j.totte@erasmusmc.nl 
 
Suzanne G.M.A. Pasmans 
Department of Pediatric Dermatology, Sophia Children’s Hospital 
Erasmus MC University Medical Center Rotterdam 
Wytemaweg 80, NL–3015 CN Rotterdam (The Netherlands) 
E-Mail s.pasmans@erasmusmc.nl 
  
Case Series 
 
Successful Treatment of Chronic 
Staphylococcus aureus-Related 
Dermatoses with the Topical 
Endolysin Staphefekt SA.100:  
A Report of 3 Cases 
Joan E.E. Totté    Martijn B. van Doorn    Suzanne G.M.A. Pasmans     
Department of Dermatology, Erasmus MC University Medical Center Rotterdam, 
Rotterdam, The Netherlands 
Keywords 
Staphefekt · Staphylococcus aureus · Endolysin · Folliculitis · Atopic dermatitis · Antibiotic 
resistance 
Abstract 
Staphylococcus aureus plays an important role in skin and soft tissue infections and contrib-
utes to the pathophysiology of complex skin disorders such as atopic dermatitis. Bacterial 
resistance against commonly used antibiotics has increased considerably in the last decades 
demanding alternative treatment approaches. We present 3 cases where patients with chron-
ic and recurrent S. aureus-related dermatoses were successfully treated with Staphefekt 
SA.100. Staphefekt SA.100 is a recombinant phage endolysin for topical skin application that 
specifically targets both methicillin-sensitive and methicillin-resistant S. aureus. As a conse-
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quence of its specific mechanism of action, bacterial resistance is unlikely to develop. In our 3 
cases, resistance induction was not observed. Our results indicate that targeted treatment 
with Staphefekt might be an attractive alternative for (long-term) classical antibiotic therapy, 
and confirmatory randomized controlled trials are warranted to evaluate its clinical efficacy 
and safety. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Staphylococcus aureus is the most common microbe causing skin and soft tissue infec-
tions and contributes to the pathophysiology of complex skin disorders such as atopic der-
matitis [1–3]. As antibiotic resistance against classical antibiotics is rapidly emerging, alter-
native treatment options are desperately needed [4–6]. Staphefekt SA.100 is a recombinant 
phage endolysin for topical skin application that specifically binds to the cell wall of S. aureus 
and cleaves bonds in the peptidoglycan wall, resulting in bacterial cell death [7]. In vitro 
studies showed that Staphefekt exclusively targets S. aureus without affecting other (com-
mensal) skin bacteria. Induction of resistance was not observed and is also not expected due 
to its specific mechanism of action [7–9]. Staphefekt is currently registered as a (class 1) 
medical device in Europe and is available in a cetomacrogol-based cream and in a gel as 
over-the-counter treatment. Evidence for its clinical efficacy is currently based on question-
naire studies and patient reviews only (Table 1) [8–10]. In this report we describe 3 cases 
with difficult-to-treat chronic or recurrent S. aureus-related dermatoses requiring antibiotic 
therapy that were successfully treated with Staphefekt SA.100 in our clinic.  
Case Presentation 
Case 1 
The first patient is a 23-year-old male with a history of osteosarcoma at the age of 16 
and acne vulgaris of the face and trunk. He presented with an extensive papulopustular 
eruption on the trunk consistent with bacterial folliculitis. Consecutive empirical treatments 
with clarithromycin 500 mg once daily combined with Betadine scrub resulted in moderate 
improvement. However, after discontinuing treatment the symptoms recurred within 3 
days. Taking into consideration the patient’s reluctance to use continuous oral antibiotics 
and after discussing the alternative (on- and off-label) treatment options, our patient decid-
ed to try a short course of Staphefekt. He applied the cream twice daily on the affected skin 
for 2 weeks. At his return visit he reported a strong decrease of inflammatory symptoms that 
started within a few days. This triggered us to further investigate the clinical effect of Staph-
efekt using clinical photographs and bacterial cultures in this and 2 other cases. One week 
after he had stopped treatment with Staphefekt, the papules and pustules recurred and were 
similar to those at the baseline (visit 1; Fig. 1a). Staphefekt was restarted twice daily, again 
resulting in a clear decrease in the number of the papules and pustules observed 4 weeks 
later (visit 2). This improvement continued up to visit 3 after another 4 weeks (Fig. 1b). Na-
sal cultures showed persistent carriage of S. aureus. Skin cultures were only taken at visits 2 
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and 3 with a positive culture at visit 3. An extra skin culture was taken 2 months later (visit 
4) to determine minimal inhibitory concentrations of Staphefekt. The minimal inhibitory 
concentrations of the cultured S. aureus strain at visits 3 and 4 was stable, indicating the 
absence of resistance during long-term daily therapy. 
Case 2 
The second patient, a 63-year-old male, was diagnosed with a secondary bacterial infec-
tion (impetigo) of his nummular eczema, mainly located at the face and the extremities. The 
diagnosis was confirmed by histopathology and S. aureus cultured from a lesion. Treatment 
with clarithromycin 250 mg twice daily during 7 days, combined with topical fusidic acid 
cream, did not result in clinical improvement. Oral prednisolone 30 mg once daily for 2 
weeks combined with flucloxacillin 500 mg 4 times daily during 7 days resulted in clinical 
improvement. However, 2 days after the treatment was stopped, the symptoms recurred 
(Fig. 2a). After discussing the alternative treatment options, Staphefekt cream was started 
twice daily on the affected skin of the face and extremities, and the extremities were addi-
tionally treated with betamethasone ointment once daily. The patient reported improve-
ment of the superinfection within 1 week. His symptoms did not recur over a treatment pe-
riod of more than 12 weeks (Fig. 2b), and he did not report any adverse effects. Although the 
superinfection had cleared, the underlying eczema at the extremities remained. His eczema 
gradually improved after the treatment with betamethasone ointment was replaced with 
tacrolimus 0.1% ointment in tar 10% (solutio carbonis detergens) 1 month later. Cultures 
from the facial skin lesions and nose collected at baseline, and after 6 and 12 weeks of treat-
ment were all positive for S. aureus.  
Case 3 
The third case is a 23-year-old man who presented with a bacterial folliculitis of the 
lower legs. S. aureus was cultured from a pustule but also from his nose and perineum. The 
patient was diagnosed with nummular eczema mainly at the extremities, which was active at 
the time of presentation. His medical history comprised biliary atresia followed by a liver 
transplant and chronic use of oral immunosuppressive medication. Class 2–3 topical cortico-
steroids, topical tacrolimus, and an emollient were prescribed to treat the eczema. The fol-
liculitis was treated with topical fucidic acid cream, oral flucloxacillin for 1 week, and Beta-
dine scrub, resulting in an improvement of the symptoms. An exacerbation 6 months later 
with follicular pustules at the lower legs was treated again with flucloxacillin but 2 months 
later the folliculitis recurred again, including extended perifollicular pustules that evolved to 
large confluent plaques at the lower legs (visit 1). After discussing the alternative treatment 
options, we started topical Staphefekt twice daily. Three weeks later (visit 2) he reported a 
strong improvement of his symptoms starting 4 days after initiation of the treatment. Clini-
cal examination at this time showed the remaining extensive eczematous lesions, but pus-
tules were clearly absent and the redness of the lesions was significantly reduced. With con-
tinued treatment, further improvement of the eczema and absence of pustules were report-
ed after 1 month. At visit 3, 2 months later, an increase of the eczema was reported. This was 
probably related to a lack of adherence since our patient used the corticosteroid cream, tac-
rolimus ointment, and emollient inconsistently. The legs showed dry eczematous lesions and 
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postinflammatory hyperpigmentation. However, pustules were still absent. Cultures of the 
skin taken at visits 1, 2, and 3 were all positive for S. aureus. 
Discussion 
This case series describes the successful treatment of S. aureus-related dermatoses with 
an antibacterial endolysin, which is currently available as an over-the-counter medical de-
vice. All 3 patients had recurrent S. aureus infections despite adequate antibiotic treatment. 
Atopic predisposition and nasal carriage of S. aureus probably contributed to the chronicity 
of their symptoms [2, 3, 11]. Despite the improvement of symptoms in these patients, S. au-
reus was still cultured from their skin during and after treatment with Staphefekt. We be-
lieve that Staphefekt induces a clinically relevant reduction of S. aureus rather than a total 
eradication. In addition, it is well-known that the skin lesions can get recolonized quickly 
due to constant exposure to S. aureus from the nose and environment. Apparently, complete 
and sustained eradication is not necessary to achieve clinically relevant improvement with 
an endolysin-based topical treatment. Since the results from our cultures are only qualitative 
in nature, future studies should further investigate the effect of Staphefekt on the S. aureus 
load and composition of the microbiome, using quantitative methods and sequencing tech-
nologies. 
Clinical symptoms quickly reappeared both after stopping antibiotics (cases 1 and 2) 
and Staphefekt (case 1), likely due to rapid S. aureus recolonization to a clinically relevant 
state. The positive clinical effect after restarting S. aureus suppression with Staphefekt in 
case 1 supports this hypothesis. Concurrent treatment of the nostrils combined with treat-
ment of the complete skin surface could potentially further reduce recolonization. 
It should be noted that both impetiginized eczema and folliculitis have a naturally fluc-
tuating disease course, which complicates the interpretation of our data. However, all 3 pa-
tients visited our outpatient clinic frequently with recurring and continuous symptoms (de-
spite adequate treatment) for long periods already before the start of Staphefekt treatment 
(10, 3.5, and 13 months). This suggests that remission is likely due to the use of Staphefekt 
rather than to chance. 
Although limited by its uncontrolled design, this case series illustrates that topical ther-
apy with Staphefekt SA.100 to continuously suppress S. aureus can lead to the reduction and 
prevention of clinical symptoms in 3 cases of S. aureus-related skin conditions, folliculitis 
and impetiginized dermatitis. Importantly, Staphefekt targets both methicillin-sensitive and 
methicillin-resistant S. aureus but does not interfere with the commensal skin microbes and 
is also not expected to induce bacterial resistance due to its specific mechanism of actions [8, 
9]. It could therefore be considered as a feasible alternative for S. aureus-related superficial 
skin infections, since classical (long-term) antibiotic therapy is clearly associated with the 
induction of bacterial resistance and other adverse effects [4, 5]. The observed beneficial 
clinical effect of Staphefekt in these cases is encouraging, and further study of its efficacy and 
safety is warranted in randomized controlled clinical trials. 
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Statement of Ethics 
The patients described in this case report provided informed consent.  
Disclosure Statement 
The Department of Dermatology of the Erasmus MC University Medical Center Rotter-
dam received an unrestricted grant from Micreos Human Health, the Netherlands, to per-
form clinical studies with Staphefekt SA.100. Micreos Human Health provided Staphefekt 
SA.100 for the patients. 
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Fig. 1. Folliculitis. a Baseline; extensive follicular papules and pustules. b After 8 weeks; few follicular pap-
ules, postinflammatory hyperpigmentation, and scarring. 
 
 
 
Fig. 2. Nummular eczema with secondary infection. a Baseline; erythematosquamous nummular lesions 
forming confluent plaques covered with crustae and swelling of the ear. b Six weeks later; very mild ery-
thematous macula with minimal scaling. 
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Table 1. Overview of in vitro and clinical studies with Staphefekt 
    
    
Authors, year Published in  Summary of findings 
    
    
Herpers et al.,  
2014 [8] 
Abstract R144 at the 24th 
European Congress of Clinical 
Microbiology and Infectious 
Diseases (ECCMID), Barcelona 
 Lysis of S. aureus by Staphefekt is dose dependent, specific, and efficient, 
compared to control strains of coagulase-negative staphylococci (in vitro) 
MSSA and MRSA proved to be equally susceptible to the endolysin 
Induction of resistance against Staphefekt could not be achieved in vitro 
        Herpers et al.,  
2014 [9] 
Summary of presentation at 
EuroSciCon meeting, London 
 In 3 out of 7 patients with rosacea, S. aureus was cultured from a lesion; 
after the local application of Staphefekt for 1 week, S. aureus was 
eradicated from the lesion in all 3 patients 
In 6 out of 8 patients with recurring dermatitis (3 constitutional eczema, 
2 chronic contact dermatitis, and 1 perioral dermatitis), S. aureus was 
found in skin cultures before treatment; in 5 of 6 patients, symptoms 
decreased during treatment with Staphefekt, and patients reported less 
need of corticosteroids 
        Totté et al.,  
2015 [10] 
Abstract P1212 at 24th EADV 
Congress, Copenhagen 
 Patients with rosacea (n = 112) and acne (n = 56) reported an 
improvement of inflammation-related symptoms and quality of life 
(Skindex-29) after 6 weeks of topical treatment with Staphefekt SA.100 in 
a prospective questionnaire study 
        Pasmans et al.,  
2016 [12] 
Study protocol randomized 
controlled trial, registered at 
ClinicalTrials.gov, 
NCT02840955 
 Ongoing double-blinded randomized controlled trial aiming to assess the 
difference in the need for corticosteroid cotherapy between the 
Staphefekt and a placebo group over a 12-week treatment period 
Secondary objectives include differences in clinical efficacy, quality of life, 
microbial composition, and safety and tolerability 
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